NCT00342797View on ClinicalTrials.gov

Retinoblastoma Biomarker Study

CompletedOBSERVATIONAL
Enrollment

2,136

Participants

Timeline

Start Date

November 17, 1993

Primary Completion Date

March 6, 2024

Study Completion Date

March 6, 2024

Conditions
RetinoblastomaMelanomaSarcoma
Trial Locations (4)

10021

Memorial Sloan-Kettering Cancer Center, New York

20892

National Cancer Institute (NCI), Bethesda

27703

Social Scientific Systems, Inc., Durham

02114-3096

Massachusetts Eye and Ear Infirmary, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00342797 - Retinoblastoma Biomarker Study | Biotech Hunter | Biotech Hunter